Visualizing Galectin-3 Binding Protein Expression with ImmunoPET
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.3c00241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Outi Keinänen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Hunter College, City University of New York, New York 10021, New York, United States. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immunoconjugates, Lung Neoplasms, Melanoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NCRR NIH HHS.
Abstract (Originalsprache)
Galectin-3 binding protein (Gal-3BP) is a glycoprotein that is overexpressed and secreted by several cancers and has been implicated as a marker of both tumor progression and poor prognosis in melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and breast cancer. The expression of Gal-3BP by a variety of neoplasms makes it an enticing target for both diagnostics and therapeutics, including immuno-positron emission tomography (immunoPET) probes and antibody-drug conjugates (ADCs). Herein, we report the development, in vitro characterization, and in vivo evaluation of a pair of Gal-3BP-targeting radioimmunoconjugates for 89Zr-immunoPET. A humanized anti-Gal-3BP antibody, 1959, and its corresponding ADC, 1959-sss/DM4 (DM4 = ravtansine), were modified with desferrioxamine (DFO) to yield DFO-1959 and DFO-1959-sss/DM4 immunoconjugates bearing 1-2 DFO/monoclonal antibody. Both DFO-modified immunoconjugates retained their affinity for Gal-3BP in enzyme-linked immunosorbent assay experiments. The chelator-bearing antibodies were radiolabeled with zirconium-89 (t1/2 ≈ 3.3 d) to produce radioimmunoconjugates ─ [89Zr]Zr-DFO-1959 and [89Zr]Zr-DFO-1959-sss/DM4 ─ with high specific activity (>444 MBq/mg, >12 mCi/mg) and stability (>80% intact after 168 h in human serum at 37 °C). In mice bearing subcutaneous Gal-3BP-secreting A375-MA1 xenografts, [89Zr]Zr-DFO-1959 clearly delineated tumor tissue, reaching a maximum tumoral activity concentration (54.8 ± 15.8%ID/g) and tumor-to-background contrast (tumor-to-blood = 8.0 ± 4.6) at 120 h post-injection. The administration of [89Zr]Zr-DFO-1959 to mice bearing subcutaneous Gal-3BP-expressing melanoma patient-derived xenografts produced similarly promising results. [89Zr]Zr-DFO-1959 and [89Zr]Zr-DFO-1959-sss/DM4 exhibited nearly identical pharmacokinetic profiles in the mice bearing A375-MA1 tumors, though the latter produced higher uptake in the spleen and kidneys. Both [89Zr]Zr-DFO-1959 and [89Zr]Zr-DFO-1959-sss/DM4 effectively visualized Gal-3BP-secreting tumors in murine models of melanoma. These results suggest that both probes could play a role in the clinical imaging of Gal-3BP-expressing malignancies, particularly as companion theranostics for the identification of patients likely to respond to Gal-3BP-targeted therapeutics such as 1959-sss/DM4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Hunter College, City University of New York, New York 10021, New York, United States.
- Department of Chemistry, University of Helsinki, Helsinki 00014, Finland.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York 10065, New York, United States.
- Ph.D. Program in Biochemistry, Graduate Center of the City University of New York, New York 10016, New York, United States.
- Ph.D. Program in Chemistry, Graduate Center of the City University of New York, New York 10016, New York, United States.
- Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Chieti 66100, Italy.
ORCID-Profile: Outi Keinänen, Brian M Zeglis
Förderung
- NCI NIH HHS
- NIH HHS
- NCRR NIH HHS
- NIEHS NIH HHS
- National Cancer Institute
- Fondazione AIRC per la ricerca sul cancro ETS
- Universit? degli Studi dell'Aquila
- Academy of Finland
Zitieren
APA
Keinänen, O., Sarrett, S. M., Delaney, S., Rodriguez, C., Dayts, E. J., Capone, E., Sauniere, F., Ippoliti, R., Sala, G., Iacobelli, S., & Zeglis, B. M. (2023). Visualizing Galectin-3 Binding Protein Expression with ImmunoPET. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00241
Vancouver
Keinänen O, Sarrett SM, Delaney S, Rodriguez C, Dayts EJ, Capone E, et al. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00241
BibTeX
@article{Keinnen2023,
author = {Keinänen, Outi and Sarrett, Samantha M and Delaney, Samantha and Rodriguez, Cindy and Dayts, Eric J and Capone, Emily and Sauniere, Frederic and Ippoliti, Rodolfo and Sala, Gianluca and Iacobelli, Stefano and Zeglis, Brian M},
title = {Visualizing Galectin-3 Binding Protein Expression with ImmunoPET},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.3c00241}
}
EUVIMED